We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Carbapenem-Resistant K. Pneumoniae Driven by Nosocomial Spread

By LabMedica International staff writers
Posted on 15 Aug 2019
Public health interventions to control the current epidemic of carbapenem-resistant Klebsiella pneumoniae rely on a comprehensive understanding of its emergence and spread over a wide range of geographical scales.

The number of deaths attributed to carbapenem-resistant K. More...
pneumoniae is on the rise in Europe. In 2007, about 341 deaths there were caused by the bacterium, but in 2015, nearly 2,100 deaths were. In a recent study, hospitals are thought to be a central link in the spread of drug-resistant K. pneumoniae in Europe.

A team of infectious disease specialists led by the University of Freiburg (Freiburg, Germany) collected more than 1,700 bacterial samples from 250 hospitals in 32 countries. Their phylogenetic analysis uncovered four clonal lineages of carbapenem-resistant K. pneumoniae and found that hospitals are a transmission hot spot, which indicates better infection control in hospitals is needed. The hospital laboratories across Europe were asked to submit their first 10 consecutive isolates of either K. pneumoniae or Escherichia coli that were not susceptible to carbapenem alongside isolates from the same species that were susceptible to carbapenem for analysis.

The team reported that overall, 55% of the isolates submitted were thought to be non-susceptible to carbapenem and 455 were thought to be susceptible, and 96% of the isolates belonged to K. pneumoniae sensu stricto. They examined the isolates' genomes for known β-lactam resistance factors, and most of the isolates, 684 of them, carried one or more carbapenemase genes like blaKPC-like and blaOXA-48-like, among others. Most of these carbapenemase gene-containing strains, further, belonged to four K. pneumoniae lineages making up sequence types 11, 15, 101 and ST258/512, and their derivatives.

The investigators measured the genetic relatedness of their samples, and found that their genetically nearest neighbor was from the same hospital for 159 of the 311 isolates carrying the blaKPC-like gene, for 125 of the 248 isolates carrying the blaOXA-48-like gene, for 43 of 79 of those with the blaNDM-like gene, and for 42 of 56 carrying the blaVIM-like gene. This, they said, is indicative of frequent hospital transmissions.

Hajo Grundmann, PhD, a professor and co-senior author of the study, said, “We are optimistic that with good hospital hygiene, which includes early identification and isolation of patients carrying these bacteria, we can not only delay the spread of these pathogens, but also successfully control them. This study emphasizes the importance of infection control and ongoing genomic surveillance of antibiotic-resistant bacteria to ensure we detect new resistant strains early and act to combat the spread of antibiotic resistance.” The study was published on July 29, 2019, in the journal Nature Microbiology.

Related Links:
University of Freiburg


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.